Background: Limited data exist on drug resistance and antiretroviral treatment (ART) outcomes in HIV-1-infected children in West Africa. We determined the prevalence of baseline resistance and correlates of virologic failure (VF) in a cohort of ART-naive HIV-1-infected children <10 years of age initiating ART in Mali. Methods: Reverse transcriptase and protease genes were sequenced at baseline (before ART) and at 6 months. Resistance was defined according to the Stanford HIV Genotypic Resistance database. VF was defined as viral load ≥1000 copies/mL after 6 months of ART. Logistic regression was used to evaluate factors associated with VF or death >1 month after enrollment. Post hoc, antiretroviral concentrations were assayed on baseline samples of participants with baseline resistance. Results: One-hundred twenty children with a median age 2.6 years (interquartile range: 1.6-5.0) were included. Eighty-eight percent reported no prevention of mother-to-child transmission exposure. At baseline, 27 (23%), 4 (3%) and none had non-nucleoside reverse transcriptase inhibitor (NNRTI), nucleoside reverse transcriptase inhibitor or protease inhibitor resistance, respectively. Thirty-nine (33%) developed VF and 4 died >1 month post-ART initiation. In multivariable analyses, poor adherence [odds ratio (OR): 6.1, P = 0.001], baseline NNRTI resistance among children receiving NNRTI-based ART (OR: 22.9, P < 0.001) and protease inhibitor-based ART initiation among children without baseline NNRTI resistance (OR: 5.8, P = 0.018) were significantly associated with VF/death. Ten (38%) with baseline resistance had detectable levels of nevirapine or efavirenz at baseline; 7 were currently breastfeeding, but only 2 reported maternal antiretroviral use. Conclusions: Baseline NNRTI resistance was common in children without reported NNRTI exposure and was associated with increased risk of treatment failure. Detectable NNRTI concentrations were present despite few reports of maternal/infant antiretroviral use.
B
efore 2010, World Health Organization (WHO) guidelines recommended non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line regimens for all HIV-infected children meeting criteria for antiretroviral therapy (ART) initiation. 1 In response to data showing that children with prior nevirapine (NVP) exposure had higher rates of treatment failure with NNRTI-based versus protease inhibitor (PI)-based ART, the guidelines were updated in 2010 to include PI-based regimens as preferred first-line ART in children <24 months of age with prior NNRTI exposure via prevention of mother-to-child transmission (PMTCT). 2, 3 Subsequent evidence favoring PI-based first-line ART even in children without prior NVP exposure informed the 2013 WHO recommendation of PI-based first-line ART in all children <36 months of age irrespective of their NNRTI exposure history. 4, 5 While access to ART in resource-limited nations has greatly improved, new challenges include sustainability of effective treatment and management of therapeutic failure. Treatment failure in HIV-infected children in resource-limited nations, estimated to be 26%-50%, is thought to be due to a combination of poor adherence, inadequate drug levels and acquired resistance from maternal ART exposure. [6] [7] [8] [9] [10] Additionally, HIV-infected breastfeeding infants of ARTtreated mothers are at increased risk of multiclass resistance. 11 Baseline NNRTI resistance rates are high in programs with high PMTCT coverage, but these rates drop precipitously after 18 months of age, suggesting that baseline resistance is mainly because of NNRTI exposure through PMTCT and not transmitted resistance. 12 Based on these data, and the undesirable attributes of PI-based regimens, including poor palatability and cold chain requirements, current guidelines recommend NNRTI-based first-line ART for children ≥36 months of age. Baseline resistance testing is not recommended because of its limited availability and dearth of knowledge about its drivers and impact on outcomes. The aim of this study is to determine the prevalence of
MATERIALS AND METHODS
Between November 2010 and February 2013, HIV-infected children <10 years of age initiating ART were recruited from the Gabriel Touré Hospital outpatient pediatric HIV clinic and one satellite clinic in Bamako, Mali. The clinics provide ART, prophylaxis and management of opportunistic infections, CD4 count and viral load (VL) testing, if available, free of charge to all children ≤15 years of age. The Institutional Review Boards of University of Bamako School of Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago and University of Washington approved this study.
Study Design and Patients
Participants who had previously received ART (except for PMTCT) were excluded. Written informed consent was obtained from the participant's guardian. Participants were evaluated at baseline (before ART initiation) and after 6 months of ART. Demographic and clinical informations were obtained at both visits. VL and CD4 counts at both visits, if available, were extracted from the medical record. VL testing was performed as part of the study at the 6-month visit. At both visits, blood samples were obtained, and plasma was stored at −20°C for future resistance testing. During the study period, first-line ART in Mali mirrored WHO 2010 guidelines: lopinavir/ ritonavir + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for children <24 months and NNRTI-based regimens for children ≥24 months, irrespective of PMTCT exposure history. Medication adherence and toxicity data are collected monthly after ART initiation as standard of care; these data were extracted from the medical record.
Laboratory Assays
Six-month VL measurements were performed at the Centre de Recherche et Formation at the University of Bamako using the Abbott Molecular m2000 RealTime Assay (Abbott Molecular, Abbott Park, IL). Genotypic resistance testing was performed on baseline samples and for participants with VL ≥1000 copies/ mL at the 6-month visit at the Pitié-Salpêtrière Hospital in Paris, France. An in-house sanger population sequencing was performed using the French Agency for HIV Research and Hepatitis technique (http://www.hivfrenchresistance.org/ANRS). Automated nucleic acid extraction was done with NucliSENS easyMAG (Biomerieux, Lyon, France) for HIV RNA isolation. Two polymerase chain reaction (PCR) runs (first PCR and nested PCR) were performed on a 9700PE (Thermo Fisher, Uden, The Netherlands) to generate an amplicon containing protease and reverse transcriptase genes. PCR products were sequenced using BigDye Terminators v3.1 on an ABI 3730 Genetic Analyzer (Applied Biosystems, Foster City, CA). Consensus sequences were aligned and edited using SmartGene HIV software (Innovation Park, Lausanne, Switzerland). Resistance was defined as presence of mutations associated with intermediate or high-level drug resistance, using the Stanford algorithm version 7.0 (Stanford University, Palo Alto, CA) (http://hivdb.stanford.edu/).
Post hoc assessment for unreported exposure to antiretrovirals (ARVs) before ART initiation was performed on baseline samples from participants with baseline resistance, including the following locally available ARVs: efavirenz, NVP, zidovudine, abacavir, emtricitabine, lamivudine, didanosine, stavudine, lopinavir and ritonavir (lower limit of detection <10 ng/mL). Plasma concentrations were determined using liquid chromatography coupled with tandem mass spectrometry (Waters Acquity UPLC and Acquity TQD, Waters Corp., Milford, MA) in the Department of Pharmacology at the Bichat-Claude Bernard Hospital in Paris, France.
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Statistical Methods
Descriptive statistics were calculated for variables of interest, including cross-tabulation with respect to the main endpoint of virologic failure (defined as VL ≥1000 copies/mL at/after 6 months) or death >1 month after enrollment, and to the main variable of interest (baseline NNRTI resistance). To evaluate bivariate associations with the endpoint and with NNRTI resistance, Fisher exact test was used for categorical variables and Wilcoxon-MannWhitney test for quantitative variables.
To further evaluate the effect of baseline NNRTI resistance on the main endpoint, multivariable logistic regression was used, adjusting for basic demographics (gender, age at enrollment and distance from clinic) and key variables suspected a priori of affecting the endpoint (adherence and presence of an NNRTI in the initial regimen). An interaction term between the use of NNRTI-based ART and baseline NNRTI resistance was added because the risk of failure was assumed to vary by ART regimen. Distance of residence from clinic was categorized as <5, 5-10 and >10 km. Poor adherence was defined as report of missed or late doses in more than 1 out of the 6-month study period. Given the small sample size and prevalence of missing data for some variables, no automated model selection methods were used. Sensitivity analyses included excluding early death from the endpoint and expanding the definition of failure to VL ≥40 and ≥400 copies/mL. A P value of <0.05 was considered significant.
To compare the rates of virologic, immunologic and clinical failure, participants were classified as meeting immunologic and/ or clinical failure criteria based on 2013 WHO guidelines. 5 Immunologic failure was defined as 6-month CD4 count <750 cells/mm 3 for children <1 year of age, <500 cells/mm 3 for children ≥1 and <2 years of age, <200 cells/mm 3 for children ≥2 and <5 years of age and <100 cells/mm 3 for children ≥5 years of age. Clinical failure was defined as WHO stage 3 or 4 at 6 months after having a lower WHO stage at baseline. The analytical dataset was derived from the raw data using SAS 9.4 (SAS Institute, Cary, NC) and R 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria). All subsequent analyses were performed using R, versions 3.2.1-3.3.1.
RESULTS
One-hundred fifty ART-naive participants were enrolled; baseline resistance testing was available for 139 (93%). Five participants died within 1 month of ART initiation, 8 were lost to follow-up and 6 did not have a 6-month blood sample, leaving 120 participants to include in the final analysis. As there were no significant differences for any of the baseline characteristics between participants included and excluded in the final model, only baseline characteristics of the 120 participants included in the final model are described in Table 1 .
At baseline, 27 of 120 (23%) participants had NNRTI resistance, and 4 (3%) had NRTI resistance (Fig. 1) . None had PI resistance, and only 2 had >1 NNRTI resistance mutation. The most common NNRTI mutations were K103N (16) and Y181C (6) found in 22 of 27 (81%) participants with any NNRTI resistance. Based on the Stanford algorithm, 23 (19%) had high-level resistance to NVP and 16 (13%) had high-level resistance to efavirenz. All 4 with NRTI resistance also had NNRTI resistance. Among participants ≥36 months of age (n = 56) at ART initiation, 9 (16%) had baseline NNRTI resistance and 3 (5%) had NRTI resistance.
There was no association between gender, WHO stage, breastfeeding status, PMTCT exposure or maternal postnatal ART and baseline NNRTI resistance. Participants with baseline NNRTI resistance were younger than those without; median age 2.4 versus 2.8 years (P = 0.02) with 29% of all participants <2 years of age and 19% of all ≥2 years of age harboring baseline NNRTI resistance (P = 0.19). Baseline NNRTI resistance was similar (22%) among participants who initiated NNRTI-or PI-based ART.
The majority of participants initiated NNRTI-based ART (Table 1) ; 4 of 45 participants <2 years of age (9%) and 68 of 75 (91%) ≥2 years of age. Two (1.6%) participants switched from NNRTI-based to PI-based regimens, 9 (7.5%) switched from PI-based to NNRTIbased regimens and 1 switched from NNRTI-based to a triple NRTIbased regimen. The most commonly cited reason for PI to NNRTI switch was medication intolerance. Rates of poor adherence were similar with NNRTI-based versus PI-based ART (21%).
Four (3%) participants died after >1 month of ART: 3 of unknown causes and 1 from tuberculosis. At 6 months, 43 (36%) had the composite outcome of virologic failure or death (Table 2 ). In participants with and without the composite outcome, there was no significant difference in proportion of participants <2 versus ≥2 years of age (P = 0.46). Five participants had clinical failure; only 2 of these experienced virologic failure. Only 2 participants experienced immunologic failure.
Resistance testing was performed in 37 of 39 participants with virologic failure [median VL: 4.8 log copies/mL, interquartile range (IQR): 3.9-5.52]; samples for 2 participants were not amplifiable. Of the 37 participants tested, 26 (70%) had both NNRTI and NRTI resistance; 3 (8%) additional participants had NRTI resistance only. The most common NNRTI mutations at 6 months remained were K103N (16) and Y181C (8), constituting 22 of 26 (85%) participants with NNRTI resistance. Twenty-five of 37 (67%) participants tested had resistance to NVP, 17 (46%) had resistance to efavirenz and 3 (8%) had resistance to rilpivirine. Seventeen of 26 (65%) participants with 6-month resistance also harbored baseline NNRTI resistance. None of the 20 failing participants receiving PI-based ART developed PI resistance after 6 months of ART.
Results of the univariate analysis are presented in Table 2 . Maternal postnatal ART was associated with virologic failure (P = 0.04); however, it was not included in the final model, because data were missing for 11 mothers and adding it to the model did not change the main effect. In multivariable analyses, poor adherence, baseline NNRTI resistance among children who initiated NNRTIbased ART (odds ratio: 22.9, P < 0.001) and initiation of PI-based ART among children without baseline NNRTI resistance (odds ratio: 5.8, P = 0.018) were significantly associated with virologic failure or death (Table 3) . Children with baseline NNRTI resistance who initiated PI-based therapy had higher odds of virologic failure or death, but this was not statistically significant. Excluding early death from the endpoint did not significantly change the point estimates (data not shown). Using a VL cutoff of ≥400 copies/mL, the associations seen in the main model remained significant, but the observed point estimates were attenuated (data not shown).
ARV concentrations were assayed in 26 of 27 participants with baseline NNRTI resistance. Ten (38%) had detectable NVP [n = 8, median: 661 ng/mL (IQR: 512-1050)] or efavirenz [n = 2, median: 179 ng/mL (IQR: 144-213)]. Compared to those without detectable ARVs, those with detectable levels were younger [median age: 1.33 (IQR: 1.06-2.5) vs. 2.56 years (IQR: 1.65-3.34), P = 0.07] and more likely to be currently breastfeeding (70% vs. 12.5%, P = 0.009). Of the participants who had previously breastfed, the time since weaning for those with detectable drug(s) was www.pidj.com | e261 similar to those without detectable drug (range: 1.12-1.76 vs. 0.13-3.08 years). There was no association between maternal receipt of peri-or postpartum ARVs or infant receipt of ARVs for PMTCT and presence of detectable drug at baseline. Of the 7 participants who had detectable drug at baseline and were currently breastfeeding, 5 had no reported history of maternal ARV administration.
DISCUSSION
We found a high rate of drug resistance in HIV-infected children initiating first-line ART in Mali, with NNRTI resistance present at baseline in 23%. In addition, among children receiving NNRTI-based ART, baseline NNRTI resistance was associated with increased odds of virologic failure after 6 months of first-line ART.
In a cohort of newly diagnosed HIV-infected children <2 years of age in South Africa, 46% had baseline NNRTI resistance and 13% had baseline NRTI resistance. 12 After stratifying by PMTCT exposure, 24% and 11% of PMTCT-unexposed children harbored baseline NNRTI and NRTI mutations, respectively, rates comparable to our results predominantly in PMTCT-unexposed and older children. When stratifying by age <2 or ≥2 years, we found baseline NNRTI resistance in 29% and 19%, respectively, and NRTI resistance in 2% and 4%, respectively.
The high rates of baseline NNRTI resistance in our cohort are noteworthy because prior surveillance studies of baseline resistance in ART-naive adults in Mali demonstrated only a 1.5%-4% and 1%-4% prevalence of baseline NNRTI and NRTI resistance, respectively. 14, 15 This suggests that perinatal transmission of resistant virus is not the dominant source of the baseline resistance in our study. NNRTI resistance secondary to single-dose NVP (sdNVP) for PMTCT typically decays by 24 months. [16] [17] [18] The fact that we saw a high rate of baseline NNRTI resistance in children ≥36 months of age strongly suggests that PMTCT exposure alone does not explain our results. ARV exposure outside PMTCT is the other plausible explanation for some of the resistance observed in our study. In fact, 37% of children with baseline NNRTI resistance had detectable levels of NVP and/or efavirenz at baseline. In many of these children, breastfeeding was the likely source of ARV exposure. However, only 70% of children with detectable drug were currently breastfeeding, and among them, only 20% reported maternal postpartum ART. Studies of breastfeeding infants of ART-treated mothers have demonstrated detectable levels of NRTIs and NNRTIs. [19] [20] [21] [22] [23] [24] Tenofovir, lamivudine and efavirenz are detectable in breastfeeding infants at 6 months but by 12 months of age are below the limit of quantification despite continued exposure via breastfeeding, likely because of maturation of the infant metabolic clearance system. 23 In our study, half of the children with detectable drug were either not currently breastfeeding or reported no maternal postpartum ART, and all were >12 months of age, raising the possibility of surreptitious or other unreported exposure to ARV drugs, as has been described in adults. 25 Regardless of the source of the resistant virus, it is concerning that 9% of our cohort who would qualify for NNRTI-based first-line ART in the current WHO guidelines harbored NNRTI resistance. Our study employed population consensus sequencing capable of detecting variants that constitute at least 20% of the viral pool, and children with low-level resistance according to the Stanford algorithm were not considered resistant in our analysis. Prior studies have shown that allele-specific PCR can detect up to 10% more resistance-associated mutations than population sequencing. 17 Thus, we would have likely detected more baseline NNRTI resistance had we used ultrasensitive PCR or included low-level resistance in our analysis.
K103N is the predominant NNRTI resistance-associated mutation detected in women exposed to sdNVP 26, 27 ; however, children are more likely to have Y181C detected after sdNVP. 17, 18, 28 In contrast to prior studies, K103N was the predominant baseline NNRTI resistance mutation in our cohort. This may reflect different resistance mechanisms and suggests that some of the baseline resistance in our cohort was transmitted. Prior studies have reported virologic failure rates of 13%-20% within 1 year of ART initiation. [29] [30] [31] The virologic failure rate of 36% observed in our study was higher, though we followed participants for only 6 months. The failure rate in our study is similar to rates observed in studies that included a longer duration of ART (>1 year) and is likely related to the higher baseline resistance in our cohort. 32 The prevalence of resistance-associated mutations at virologic failure in our cohort is similar to prior reported rates of 52%-97%. 29, 32 There are few studies examining the association between pretreatment resistance and virologic failure during ART. In Uganda, children with NNRTI resistance mutations before ART initiation were more likely to develop virologic failure compared to those without, but the difference was not statistically significant. 31 In our cohort, children with baseline NNRTI resistance mutations who initiated NNRTI-based ART were 23 times more likely to have virologic failure compared to children without NNRTI resistance. As expected, there was a weaker association between baseline NNRTI resistance and virologic failure during PI-based therapy. Because the age-regimen distribution reflects a policy similar to the current WHO guidelines, the increased odds is an indicator of the potential risk increase for patients ≥3 years of age, because of harbored NNRTI resistance. Interestingly, among children without baseline NNRTI resistance, initiating PI-based therapy was significantly associated with virologic failure. This finding persisted after controlling for adherence, though caregiver-reported adherence tends to be a poor indicator of true adherence. 33 Our study had several limitations. Very few children had baseline VL and CD4 data, which precluded their inclusion in the final model. Because the timing of HIV infection was unknown and reporting of PMTCT and postpartum maternal ART history was incomplete, we are unable to differentiate the contributions of NNRTI exposure versus transmitted resistance to our results. The fact that 37% of children with baseline NNRTI resistance had detectable levels of NVP and/or efavirenz suggests that some of the resistance was due to NNRTI exposure. As we did not measure drug levels in children without baseline NNRTI resistance, we cannot ascertain the association between drug detection and baseline resistance. Further, maternal ART and breastfeeding histories were sometimes provided by other caregivers, which limited our ability to verify the details. Nevertheless, several of our findings suggest unreported ARV drug exposure.
In conclusion, a significant proportion of ART-naive HIVinfected children in our Malian cohort harbored NNRTI-resistant virus that greatly increased the risk of virologic failure of NNRTIbased treatment. In addition, over one-third of the children with baseline NNRTI resistance had detectable NVP and/or efavirenz despite few reports of maternal ART or PMTCT and no reports of infant ART. A considerable number of children ≥36 months of age harbored baseline NNRTI-resistant virus, suggesting that resistance testing may be important whenever NNRTI-based treatment is being contemplated for this age group.
